April 3, 2017 / 11:22 AM / 7 months ago

BRIEF-Trillium Therapeutics presents TTI-621 preclinical data at AACR annual meeting

April 3 (Reuters) - Trillium Therapeutics Inc:

* Trillium Therapeutics presents TTI-621 preclinical data at AACR annual meeting and provides clinical update

* Trillium Therapeutics-currently enrolling patients in expansion phase of ongoing phase 1 trial of tti-621, in patients with multiple Hematologic malignancies

* Trillium therapeutics inc - to date, 33 evaluable patients have been enrolled into expansion phase of tti-621 trial Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below